Skip to main content
. Author manuscript; available in PMC: 2020 Apr 3.
Published in final edited form as: ACS Appl Mater Interfaces. 2019 Mar 21;11(13):12298–12307. doi: 10.1021/acsami.9b00264

Figure 4. 3D antibiotic scaffolds reduce blood-brain barrier (BBB) permeability associated with S. aureus craniotomy infection.

Figure 4.

(A) Schematic depicting the paradigm used to assess the treatment efficacy of 3D bioprinted scaffolds. (B) 3D antibiotic scaffolds (daptomycin + rifampin) were inserted at day 7 after S. aureus craniotomy infection, whereupon BBB permeability was assessed 3 or 7 days later using Evan’s blue. Results are representative of 5 mice per group.